A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab

A significant association between high blood-based tumor mutational burden (bTMB) and improved progression-free survival (PFS) was observed in advanced non-small cell lung cancer (NSCLC) receiving atezolizumab. However, this result was unrepeatable in a recent prospective study. We hypothesized that...

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Wei, Qian, Jie, Xu, Mi-Die, Gu, Kai, Qian, Fang-Fei, Hu, Min-Juan, Lu, Jun, Gan, Lu, Zhang, Xue-Yan, Cao, Shu-Hui, Li, Jing-Wen, Wang, Yue, Zhang, Bo, Wang, Shu-Yuan, Hu, Fang, Li, Chang-Hui, Zhong, Hua, Han, Bao-Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051187/
https://www.ncbi.nlm.nih.gov/pubmed/32158623
http://dx.doi.org/10.1080/2162402X.2020.1731072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051187/
https://www.ncbi.nlm.nih.gov/pubmed/32158623
http://dx.doi.org/10.1080/2162402X.2020.1731072

Ejemplares similares